Oral administration of somatostatin reduces postprandial plasma triglycerides, gastrin and gut glucagon-like immunoreactivity.
D000818:Animals; D003864:Depression, Chemical; D004285:Dogs; D004435:Eating; D005755:Gastrins / Q000097:blood*; D005934:Glucagon / Q000378:metabolism*; D007413:Intestinal Mucosa / Q000378:metabolism*; D007422:Intestines / Q000187:drug effects; D013004:Somatostatin / Q000494:pharmacology*; D013997:Time Factors; D014280:Triglycerides / Q000097:blood*
D005755:Gastrins; D014280:Triglycerides; D013004:Somatostatin; D005934:Glucagon